Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.55 |
| ▸ | POLG | P54098 | 1/20 | 0.46 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.45 |
| ▸ | DTYMK | P23919 | 2/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 2/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8185378 | 1.00 | POLB (0.59) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL29875948 | 0.94 | POLB (0.56) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL6417484 | 0.91 | POLB (0.53) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL29875815 | 0.84 | POLB (0.51) | POLBP2RY2P2RY4P2RY6PNP | |
| SCHEMBL3042901 | 0.84 | POLB (0.81) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL16699229 | 0.84 | POLB (0.81) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxyguanosine Triphosphate SCHEMBL18785123 | 0.84 | POLB (0.81) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxyguanosine Triphosphate SCHEMBL12729493 | 0.84 | POLB (0.81) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL5314160 | 0.84 | POLB (0.59) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL8091449 | 0.84 | POLB (0.59) | POLBP2RY2P2RY4P2RY6POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150389-A1 | MODIFIED GUANINES | NUCLERA LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| WO-2022175685-A1 | MODIFIED GUANINES | NUCLERA NUCLEICS LTD (GB) | 2022-08-25 | — | — | WO | disclosed |
| EP-1589028-A2 | Modified oligonucleotides, their preparation and their use | Aventis Pharma Deutschland GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| EP-0680969-B1 | Modified oligonucleotides, their preparation and their use | AVENTIS PHARMA GMBH (DE) | 2005-07-27 | — | — | EP | disclosed |
| US-5789562-A | STABLE HYBRIDIZATION COMPLEXES WITH NUCLEI ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-04 | — | — | US | disclosed |
| EP-0680969-A2 | Modified oligonucleotides, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150389-A1 | MODIFIED GUANINES | NSUN2, RNMT, RNGTT | POLB 29/4885P2RY2 1972/4885P2RY4 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.